What it sells
Bringing resuscitated drugs to market.
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical trial sites (trials contact) and pharma partners/licensors (partnerships contact).
Workflow: what inputs become what output?
Advances late-stage programs for life-threatening diseases with urgent unmet needs, using an AI-native approach.
Economics: what it saves and how it charges
UnverifiedBiopharma drug developer: value from advancing and partnering/licensing drug programs.
Distribution: how it reaches customers
Email contacts for clinical research (trials@) and partnerships/licensing (partnerships@).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-28 | — | $153-million | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.